On March 4, 2025, Calcimedica Inc. announced that in a post-hoc analysis of its Phase 2 CARDEA trial, Auxora reduced mortality by 62.7% in patients with severe COVID-19 pneumonia and Acute Kidney Injury, compared to placebo. The overall study showed a 56.3% reduction in mortality at day 30, with 261 patients involved.